

## REGENERON PHARMACEUTICALS INC

Form 424B3

February 01, 2002

Filed pursuant to Rule No. 424(b)(3)

File Number 333-74464

PROSPECTUS SUPPLEMENT NO. 1  
Regeneron Pharmaceuticals, Inc.

\$200,000,000

5.50% Convertible Senior Subordinated Notes due 2008  
and Shares of Common Stock Issuable upon Conversion of the Notes

This prospectus supplement supplements the prospectus, dated January 24, 2002 of Regeneron Pharmaceuticals, Inc. relating to the sale by certain of our securityholders (including their pledgees, donees, assignees, transferees, successors and others who later hold any of the securityholders' interests) of up to \$200,000,000 aggregate principal amount at maturity of notes and the shares of common stock issuable upon conversion of the notes. You should read this prospectus supplement in conjunction with the prospectus, and this prospectus supplement is qualified by reference to the prospectus, except to the extent that the information in this prospectus supplement supersedes the information contained in the prospectus.

The table of selling securityholders contained in the prospectus is hereby modified to add as follows:

Name	Aggregate Principal Amount at Maturity of the Notes that may be Sold	Percentage of Notes Outstanding	Number of Shares of Common Stock that may be Sold (1)
Canyon Capital Arbitrage Master Fund, Ltd.	\$1,000,000	*	33,056
Canyon MAC 18 Ltd. (RMF)	\$250,000	*	8,264
Canyon Value Realization Fund (Cayman), Ltd.	\$1,500,000	*	49,584
Canyon Value Realization Fund, L.P.	\$750,000	*	24,792
Merrill, Lynch, Pierce, Fenner and Smith Inc	\$5,000,000	2.5%	165,282
TQA Master Fund, Ltd.	\$3,750,000	1.88%	123,961
Whitebox Convertible Arbitrage Advisors, LLC	\$2,000,000	1.0%	66,113

\* Less than one percent (1%).

- (1) Assumes conversion of all of the holder's notes at a conversion rate of 33.0565 shares of common stock per \$1,000 principal amount at maturity of the notes. This conversion rate is subject to adjustment, however, as described under "Description of the Notes - Conversion of the Notes." As a result, the number of shares of common stock issuable upon conversion of the notes may increase or decrease in the future.

## Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 424B3

- (2) Calculated based on Rule 13d-3(d) (i) of the Exchange Act, using 43,826,969 shares of common stock outstanding as of December 31, 2001. In calculating this amount for each holder, we treated as outstanding the number of shares of common stock issuable upon conversion of all that holder's notes, but we did not assume conversion of any other holder's notes.

Investing in the notes or shares of common stock involves risks that are described in the "Risk Factors" section beginning on page 5 of the prospectus.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.

The date of this prospectus supplement is February 1, 2002.